Multiple myeloma diagnostic kit based on FAM210B gene

Through high-throughput mRNA expression profiling sequencing, it was found that the FAM210B gene is highly expressed in multiple myeloma, and a qPCR kit based on the FAM210B gene was developed, which solved the problem of multiple myeloma diagnosis and achieved accurate early screening and diagnosis of the disease. , providing new therapeutic targets.

CN119061138APending Publication Date: 2024-12-03CAPITAL UNIVERSITY OF MEDICAL SCIENCES +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410619518.7
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-05-20
Publication Date
2024-12-03

AI Technical Summary

Technical Problem

The existing technology is difficult to effectively diagnose multiple myeloma, the pathogenesis is unclear, and the lack of key pathogenic genes and diagnostic methods, which leads to difficulty in early diagnosis of the disease.

Method used

Through high-throughput mRNA expression profiling sequencing analysis, it was found that the FAM210B gene is highly expressed in patients with multiple myeloma. A quantitative polymerase chain reaction (qPCR) amplification kit based on the FAM210B gene was designed to use the FAM210B gene expression level to perform multiple bone marrow Diagnosis of tumor.

Benefits of technology

Accurate early screening and diagnosis of multiple myeloma is achieved, new diagnostic and treatment targets are provided, and the accuracy and safety of diagnosis are improved.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119061138A_ABST
    Figure CN119061138A_ABST
Patent Text Reader

Abstract

The invention discloses a quantitative polymerase chain reaction (qPCR) amplification kit based on an FAM210B gene and application of the quantitative polymerase chain reaction (qPCR) amplification kit in diagnosis of multiple myeloma. Compared with healthy people, FAM210B is highly expressed in peripheral blood cells of multiple myeloma patients. The multiple myeloma diagnostic kit based on the FAM210B gene is prepared by using the characteristic that multiple myeloma cells highly express the FAM210B gene. The kit comprises a primer pair for amplifying an FAM210B gene and a housekeeping gene (beta-actin) and a qPCR (quantitative polymerase chain reaction) system (SYBR Green fluorescent dye, a PCR buffer solution and dNTPs). By utilizing the kit, the expression condition of the FAM210B can be rapidly and quantitatively detected, so that the condition of multiple bone marrow diseases is detected. The invention provides a diagnostic kit which is more sensitive and stable in result and simpler, more convenient and quicker to operate for early diagnosis of multiple bone marrow.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of cancer-related gene detection. More specifically, the present invention is based on the fact that the FAM210B gene is significantly upregulated in the peripheral blood of multiple myeloma patients. The present invention relates to a multiple myeloma diagnostic kit based on the FAM210B gene and the use of the FAM210B gene in the preparation of a multiple myeloma diagnostic kit. The present invention also relates to a method for diagnosing multiple myeloma. Background Art

[0002] Multiple myeloma is considered a malignant proliferative disease of plasma cells, characterized by uncontrolled proliferation of plasma cells and production of monoclonal antibodies. Multiple myeloma cells originate from plasma cells in the bone marrow, and plasma cells are cells that develop from B lymphocytes to the final functional stage. Therefore, multiple myeloma can be classified as a B lymphocyte lymphoma. It is characterized by abnormal proliferation of bone marrow plasma cells accompanied by excessive production of monoclonal immunoglobulins or light chains (M proteins). Very few patients may be non-secretory MM that does not produce M proteins. Multiple myeloma is often accompanied by multiple osteolytic lesions, hypercalcemia, anemia, and kidney damage. Because the production of normal immunoglobulins is suppressed, various bacterial infections are prone to occur.

[0003] The incidence of multiple myeloma is estimated to be 2-3 / 100,000, with a male-to-female ratio of 1.6:1, and most patients are >40 years old. In recent years, clinical investigations have found that the incidence of multiple myeloma has increased significantly. It is estimated that the incidence in the United States in 2020 will be as high as 4-6 / 100,000 cases, with 32,270 new cases and 12,830 deaths reported. The incidence in African Americans is 2-3 times that of European Americans.

[0004] As we all know, patients with multiple myeloma and other malignant diseases experience a gradual process from asymptomatic to symptomatic, which is also called the non-malignant to malignant stage. This gradual process is accompanied by changes in the expression of many genetic genes. By detecting the expression of genes related to multiple myeloma, it is possible to provide a basis for early diagnosis of multiple myeloma and prepare detection methods based on the corresponding genes.

[0005] However, due to the fact that the pathogenesis of multiple myeloma is still unclear, the disease cannot be effectively diagnosed. Therefore, it is considered crucial to study the key genes of multiple myeloma and the diagnostic methods based on key genes.

[0006] The present invention conducted high-throughput mRNA expression profile sequencing analysis on clinical samples of healthy people and multiple myeloma patients and found that FAM210B is a highly expressed new gene in multiple myeloma patients. Our previous experimental studies have shown that overexpression of the FAM210B gene can promote the proliferation of multiple myeloma cells and the occurrence and development of transplanted tumors in mice. Therefore, this gene may become a new diagnostic and therapeutic target for multiple myeloma. Summary of the invention

[0007] In order to make up for the deficiencies of existing multiple myeloma diagnostic targets, the object of the present invention is to provide a quantitative polymerase chain reaction (qPCR) amplification kit based on the FAM210B gene and its application in multiple myeloma diagnosis.

[0008] In order to achieve the above object, the present invention adopts the following technical solution:

[0009] The present invention conducts high-throughput mRNA expression spectrum sequencing analysis on peripheral blood cell samples of healthy people and multiple myeloma patients, and finds that FAM210B is a highly expressed new gene in multiple myeloma patients. By detecting the expression of the FAM210B gene transcription level, it can be determined whether the subject suffers from multiple myeloma.

[0010] Since the transcription level of FAM210B gene in peripheral blood cell samples of multiple myeloma patients is significantly higher than that in peripheral blood cell samples of healthy people, this feature can be used as a basis for preparing a multiple myeloma diagnostic kit based on the FAM210B gene. The use of FAM210B gene in preparing a multiple myeloma diagnostic kit based on the FAM210B gene is characterized in that the diagnostic kit contains a primer pair for amplifying the FAM210B gene using qPCR, and the primers are:

[0011] Upstream primer sequence: 5'-TCTCTGATGCAGGGCACTTG-3', as shown in SEQ ID NO: 1;

[0012] Downstream primer sequence: 5′-CTCAGCACGC TCCTGTTACT-3′, as shown in SEQ ID NO:2.

[0013] Another object of the present invention is to provide a multiple myeloma diagnostic kit based on the FAM210B gene, the kit comprising primers for qPCR amplification of the FAM210B gene, the primers can be designed according to conventional design principles of primer design. In a preferred embodiment, the primers are:

[0014] Upstream primer sequence: 5'-TCTCTGATGCAGGGCACTTG-3', as shown in SEQ ID NO: 1;

[0015] Downstream primer sequence: 5′-CTCAGCACGC TCCTGTTACT-3′, as shown in SEQ ID NO:2.

[0016] The diagnostic kit also contains housekeeping gene β-actin primers, and the primer pairs can be designed according to conventional design principles of primer design. In a preferred embodiment, the primers are:

[0017] Upstream primer sequence: 5'-ctcgcctttgccgatcc-3', as shown in SEQ ID NO: 3;

[0018] Downstream primer sequence: 5'-ggggtacttcagggtgagga-3', as shown in SEQ ID NO:4.

[0019] The diagnostic kit further comprises a qPCR amplification reaction system, and the qPCR amplification reaction system comprises SYBRGreen fluorescent dye, PCR buffer, and dNTPs.

[0020] In the above technical solution, the PCR buffer is a well-known prior art in the art. Preferably, the PCR buffer comprises: 200 mM (NH4)2SO4, 20 mM KCl, and 2.5 mM MgCl2.

[0021] In a specific embodiment of the present invention, the diagnostic kit of the present invention further comprises an M-MLV reverse transcription system, and the reverse transcription system comprises: a reverse transcription reaction solution, an M-MLV reverse transcriptase, an RNase inhibitor, dNTPs, and Oligo(dT).

[0022] Preferably, the reverse transcription reaction solution contains: 15 mM MgCl2, 370 mM KCL, 250 mM Tris-HCL (pH 8.3), and 50 mM DTT.

[0023] The RNase inhibitor may be any RNase inhibitor commonly used in the art, preferably a recombinant RNA protease inhibitor expressed in Escherichia coli.

[0024] In a specific embodiment of the present invention, the diagnostic kit of the present invention further comprises an RNA extraction reagent, and the RNA extraction reagent comprises Trizol, chloroform, isopropanol, and 75% ethanol.

[0025] The diagnostic kit of the present invention is stored at -20°C to minimize repeated freezing and thawing.

[0026] The present invention also provides a method for diagnosing multiple myeloma, the method comprising:

[0027] (1) Extract total RNA from samples using RNA extraction reagent;

[0028] (2) reverse transcribing the RNA obtained in step (1) into cDNA;

[0029] (3) Amplify the FAM210B gene and housekeeping gene on a qPCR instrument;

[0030] (4) Determine the target band by melting curve analysis and electrophoresis. ΔΔ Relative quantification was performed using the CT method;

[0031] (5) The expression of FAM210B gene was increased, indicating that the subjects were multiple myeloma patients.

[0032] The advantages and beneficial effects of the present invention are:

[0033] (1) The present invention is the first to discover the relationship between FAM210B and multiple myeloma. By detecting the level of FAM210B gene expression in a subject, it can be determined whether the subject suffers from multiple myeloma, thereby guiding clinicians to provide prevention or treatment plans for the subject;

[0034] (2) The present invention provides a basis for the preparation of diagnostic kits or therapeutic reagents using the FAM210B gene as a target for the first time;

[0035] (2) The present invention finds that the FAM210B diagnostic kit can diagnose multiple myeloma. Compared with existing diagnostic methods, this method has high accuracy and low side effects, which is conducive to the early screening of multiple myeloma and the accurate judgment of whether it is multiple myeloma. BRIEF DESCRIPTION OF THE DRAWINGS

[0036] Figure 1 The results show that the expression level of FAM210B mRNA in peripheral blood cells of patients with multiple myeloma is significantly upregulated. Health represents 21 peripheral blood cell samples of healthy people, MM represents 21 peripheral blood cell samples of patients with multiple myeloma, and FAM210B mRNA (Relative expression) represents the ratio of FAM210B mRNA in peripheral blood cell samples of healthy people and patients with multiple myeloma to the internal reference β-actin mRNA in each sample, and then the ratio of each sample is divided by the ratio of the first healthy sample. Each point in the figure represents a sample, and *** indicates a significant statistical analysis p value <0.001.

[0037] Specific implementation method

[0038] The present invention will be further described in detail below in conjunction with the accompanying drawings and embodiments. The embodiments of the present invention are only used to explain the present invention and are not used to limit the scope of the present invention.

[0039] The experimental methods for which specific conditions are not specified in the following examples are generally performed under conventional conditions, such as those described in Sambrook et al., Molecular Cloning: A Laboratory Manual (New York: Cold Spring Harbor Laboratory Press, 1989), or under conditions recommended by the manufacturer.

[0040] Unless otherwise specified, the materials and reagents used in the following examples can be obtained from commercial sources.

[0041] Example 1 Multiple myeloma patients highly express FAM210B

[0042] 1. Materials and Methods

[0043] 1. Materials

[0044] Peripheral blood samples from 3 patients with multiple myeloma and 3 healthy controls

[0045] 2. Methods

[0046] 2.1. Isolation of peripheral blood cells from multiple myeloma patients and healthy subjects

[0047] Peripheral blood cells from multiple myeloma patients and healthy subjects were isolated according to the instructions of the peripheral blood cell isolation kit. The main steps are as follows:

[0048] (1) Draw human peripheral blood into a heparin anticoagulant tube, take 5 mL of fresh blood, add PBS at a ratio of 1:1

[0049] Dilute the blood (usually 2mL+2mL in blood collection tube).

[0050] (2) Take 5 mL of lymphocyte separation fluid and place it in a 15 mL sterile centrifuge tube for later use.

[0051] (3) Aspirate the diluted blood and slowly add it along the wall of the test tube 1 cm above the layering liquid so that the diluted blood overlaps on the layering liquid and forms a clear interface with the separation liquid.

[0052] (4) Centrifuge at room temperature, 2000 rpm, 20 min. At this time, five layers are formed in the centrifuge tube: the top layer is plasma, and between the plasma layer and the lymphocyte separation fluid is the lymphocyte layer in the form of a white film.

[0053] (5) Carefully aspirate the mononuclear cell layer in the middle that is like a white film, and try to aspirate all the mononuclear cells. Add 5 times the volume of PBS to wash twice, centrifuging at 1500 rpm for 10 minutes each time.

[0054] (6) Remove the supernatant, add 1 mL of 1640 culture medium and mix well. Take a small amount for cell counting.

[0055] (7) Check the activity of the isolated cells with trypan blue dye: take 2 drops of cell suspension and add 1 drop of 2% trypan blue dye. After 5-10 minutes, take a sample for wet mount high-power microscopy. Living cells are not stained, while dead cells are stained blue. Count 200 cells and calculate the percentage of living cells. The activity should be above 95%.

[0056] 2.2. Extraction of total RNA from peripheral blood of multiple myeloma patients and healthy subjects

[0057] RNA was extracted from peripheral blood B cells of multiple myeloma patients and healthy subjects according to the instructions of Trizol kit. The main steps are as follows:

[0058] (1) Lyse tissue cells with cell lysis buffer and centrifuge to obtain the upper layer of cells. Add 1 ml of

[0059] For Trizol, pump the lysate 10 times using a disposable syringe with a needle.

[0060] (2) After standing for 5 minutes, add 200 μl of chloroform, mix by inverting the centrifuge tube vigorously, and stand at room temperature to allow the layers to separate. Centrifuge at 12,000 g for 5 minutes and carefully transfer the aqueous phase to a 1.5 ml centrifuge tube.

[0061] (3) Add an equal volume of isopropanol, mix thoroughly, take out 750 μl and transfer it to the adsorption column, centrifuge for 30 seconds, pour out the liquid in the collection tube, transfer the adsorption column to the same collection tube, and transfer the remaining liquid to the adsorption column.

[0062] Pour the liquid in the collection tube and transfer the adsorption column to the same collection tube.

[0063] (4) Add 500 μl RP solution and centrifuge for 30 seconds. Pour out the liquid in the collection tube and move the adsorption column into the same collection tube.

[0064] (5) Add 500 μl of W3 solution, let stand for 1 minute, centrifuge for 15 seconds. Move the adsorption column into a clean collection tube, add 500 μl of W3 solution, and centrifuge for 15 seconds.

[0065] (6) Pour out the liquid in the collection tube, move the adsorption column into the same collection tube, and centrifuge for 1 minute.

[0066] (7) Place the adsorption column in another clean 1.5 ml centrifuge tube, add 50 μl of pure water to the center of the adsorption membrane, let it stand at room temperature for 1 minute, and then centrifuge for 1 minute. Store the RNA at -70°C.

[0067] (8) Identification of total RNA integrity: Take 2 μl RNA sample and run electrophoresis on 1.5% agarose gel (80 v, 15 min). After separating the zones, stain with EB and observe the electrophoresis zones under ultraviolet light.

[0068] (9) Determine RNA concentration and purity using a nucleic acid protein analyzer

[0069] 2.3 Construction and sequencing of peripheral blood mRNA transcriptome libraries of multiple myeloma cases and healthy subjects

[0070] According to the instructions of the transcriptome library construction and sequencing kit, the total RNA of peripheral blood B cells of multiple myeloma cases and healthy subjects was constructed and sequenced. The main steps are as follows:

[0071] (1) Purify transcribed mRNA from the total RNA obtained above using QIAGEN's RNeasy MinElute Cleanup Kit. For specific steps, see the instruction manual.

[0072] (2) Using the single-end library construction method, we obtained the mRNA transcriptome library of peripheral blood B cells from multiple myeloma cases and healthy subjects.

[0073] (3) The mRNA transcriptome library was subjected to high-throughput sequencing on Illumina HiSeq 4000 to obtain 150 bp paired-end reads.

[0074] (4) Illumina Casava1.8 software was used to trim the sequence reads of the adapter sequences and filter the low complexity or low quality sequences. Bowtie 2 version 2.2.2 was used to align the human genome hg19 Refseq. Genome_build:hg19 was used to calculate the sequence size (FPKM).

[0075] (5) Use the independent tool FastQC to perform pre-calibration QC on each sample, and perform forward and reverse reads independently.

[0076] (6) Reads were trimmed using Trimmomatic by removing Illumina adapters and discarding reads with length less than 50 bases.

[0077] (7) Align the reads to the reference genome (hg19) using HISAT2.

[0078] (8) Use the MarkDuplicates function in Picards Tools to remove PCR duplicates.

[0079] (9). Counts were generated using HTSeq using human hg19-RefSeq from UCSC.

[0080] 2.4 Analysis of peripheral blood mRNA transcriptome in multiple myeloma cases and healthy subjects

[0081] (1) Using the Illumina HiSeq 4000 sequencing platform and a single-end sequencing method, we measured the mRNA transcriptome data of peripheral blood B cells in multiple myeloma cases and healthy subjects.

[0082] (2) Using the single-end library construction method, two mRNA transcriptome data sets were obtained, namely: mRNA transcriptome data of multiple myeloma case group and mRNA transcriptome data of healthy people.

[0083] (3) In order to analyze the differential expression of mRNA between multiple myeloma case group and healthy control group, each mRNA in the two mRNA transcriptomes of multiple myeloma case group and healthy control group was first standardized. The expression level after standardization = actual expression level × 1,000,000 / total number of reads in the transcriptome.

[0084] (4) Fold-change was calculated as Log2 (experimental group / control group). A fold-change value greater than 1 was considered to be up-regulated, and a fold-change value less than -1 was considered to be down-regulated.

[0085] (5) The p-value was corrected for multiple testing using significance analysis of microarray (SAM) software, and the false discovery rate (FDR) was set at ≤0.01 during the analysis.

[0086] (6) The main analysis was on the expression genes related to characteristic antibodies of multiple myeloma, such as IGHG1, IGHG2, IGHA2, IGHA1, IGHG3, IGHM, IGHE, IGHG4, and IGHD in Table 1

[0087] (7) When analyzing other associated genes, it was found that the FAM210B gene had a significant correlation, as shown in Table 1.

[0088] 2. Results

[0089] The results of peripheral blood mRNA transcriptome analysis of multiple myeloma cases and healthy controls showed that the multiple myeloma cases showed characteristic increases in IGHG1, IGHG2, and IGHA2, namely antibodies IgG1, IgG2, and IgA2. These results indicate that multiple myeloma occurs in the multiple myeloma cases. At the same time, we detected a new gene, FAM210B, which showed that its multiple increase in the multiple myeloma cases was similar to that of IGHG2 (Table 1), and it can be regarded as a feasible molecular marker for the diagnosis of multiple myeloma.

[0090]

[0091] Table 1. Expression changes of antibody genes IGHG1, IGHG2, IGHA2, IGHA1, IGHG3, IGHM, IGHE, IGHG4, IGHD and FAM210B in peripheral blood of multiple myeloma cases and healthy subjects. FPKM: total exonfragments / mapped reads (millions) / exon length (KB), Fragments per Kilo bases per Million reads. MM / Health shows the ratio of gene expression in peripheral blood of multiple myeloma cases and healthy subjects to that in peripheral blood of healthy subjects.

[0092] Example 2 Preparation of a Multiple Myeloma Diagnostic Kit Based on the FAM210B Gene

[0093] According to the correlation between FAM210B gene expression and multiple myeloma, multiple myeloma can be diagnosed by detecting the expression of FAM210B gene. Therefore, the present invention provides a kit for diagnosing multiple myeloma based on detecting FAM210B gene expression, and the components in the diagnostic kit are as follows: comprising a qPCR reaction system, and a primer pair for amplifying FAM210B gene and β-actin gene.

[0094] Primer pair for amplifying FAM210B gene:

[0095] Upstream primer sequence: 5'-ctgcagccaggacttcttca-3', as shown in SEQ ID NO: 1;

[0096] Downstream primer sequence: 5'-gtcgtagcgacagtagacgg-3', as shown in SEQ ID NO:2.

[0097] Primer pairs for amplifying β-actin:

[0098] Upstream primer sequence: 5'-ctcgcctttgccgatcc-3', as shown in SEQ ID NO: 3;

[0099] Downstream primer sequence: 5'-ggggtacttcagggtgagga-3', as shown in SEQ ID NO:4.

[0100] qPCR reaction system:

[0101] (1) PCR buffer: 20mM KCL, 2.5mM MgCL2, 200mM (NH4)2SO4

[0102] (2).dNTPs

[0103] (3).SYBR Green fluorescent dye.

[0104] When using, the reverse transcribed FAM210B gene cDNA was fused with the reagents in the PCR reaction system in advance, and the PCR reaction was performed on a qPCR instrument, set to 95℃10min, (95℃15s, 60℃60s)*45 cycles. SYBR Green was used as a fluorescent marker, and the target band was determined by melting curve analysis and electrophoresis. ΔΔ The relative quantification was performed by CT method.

[0105] Example 3 Diagnosis of multiple myeloma using the FAM210B gene diagnostic kit

[0106] 1. Materials and Methods

[0107] 1. Materials

[0108] Peripheral blood cells were collected from 21 multiple myeloma patients and 21 healthy subjects.

[0109] 2. Methods

[0110] Fluorescence real-time quantitative PCR (qPCR) was used, and the specific steps are as follows:

[0111] 2.1. Isolation of peripheral blood cells from multiple myeloma patients and healthy subjects

[0112] Peripheral blood cells from multiple myeloma cases and healthy subjects were separated according to the instructions of the peripheral blood cell separation kit. The main operating steps were as described in Example 1: 2.1, separation of peripheral blood cells from multiple myeloma cases and healthy subjects.

[0113] 2.2. Extraction of total RNA from peripheral blood cells of multiple myeloma patients and healthy subjects

[0114] Peripheral blood cells from multiple myeloma cases and healthy subjects were extracted according to the instructions of the RNA extraction kit. The main steps are as follows:

[0115] (1) Add Trizol to the cell sample and store at room temperature for 5 minutes;

[0116] (2) Add 0.2 ml of chloroform, shake the centrifuge tube vigorously, mix thoroughly, and place at room temperature for 5–10 minutes;

[0117] (3) After high-speed centrifugation at 12000rpm for 15 minutes, aspirate the upper aqueous phase (70%) into another new centrifuge tube. Be careful not to aspirate the protein between the two aqueous phases. Transfer to a new tube, add an equal volume of -20℃ pre-cooled isopropanol, invert thoroughly to mix, and place on ice for 10 minutes;

[0118] (4) After centrifugation at 12000 rpm for 15 min, discard the supernatant carefully, add 75% DEPC ethanol at a ratio of 1 ml / ml Trizol to wash the precipitate (stored at 4°C), wash the precipitate, shake and mix, and centrifuge at 12000 rpm for 5 min at 4°C;

[0119] (5) Discard the ethanol liquid, place at room temperature for 5 minutes to fully dry the precipitate, and add DEPC-treated water to dissolve the precipitate;

[0120] (6) Measure the purity and concentration of RNA using Nanodrop2000 UV spectrophotometer and store at -70°C.

[0121] 2.3. Total RNA Reverse Transcription

[0122] Reverse transcription was performed on lμg of total RNA using reverse transcription buffer to synthesize cDNA. A 25μl reaction system was used, and 1μg of total RNA was taken from each sample as template RNA. The following components were added to the PCR tube: DEPC water, 5× reverse transcription buffer, 10mmol / L dNTP, 0.1mmol / l DTT, 30μmmol / l OligodT, 200U / μl M-MLV, and template RNA. Incubate at 42℃ for 1h, 72℃ for 10min, and centrifuge briefly.

[0123] 2.4. qPCR amplification reaction

[0124] A 25 μl reaction system was used, and three parallel tubes were set up for each sample. All amplification reactions were repeated three times or more to ensure the reliability of the results. The following reaction system was prepared: 12.5 μl qPCR reaction system, 1 μl forward primer (5 μM / μl), 1 μl reverse primer (5 μM / μl), 2.0 μl template cDNA, 8.5 μl enzyme-free water; primer pair for amplifying FAM210B gene:

[0125] Upstream primer sequence: 5'-TCTCTGATGCAGGGCACTTG-3', as shown in SEQ ID NO: 1;

[0126] Downstream primer sequence: 5'-CTCAGCACGC TCCTGTTACT-3', as shown in SEQ ID NO: 2. Primer pair for amplifying β-actin:

[0127] Upstream primer sequence: 5'-ctcgcctttgccgatcc-3', as shown in SEQ ID NO: 3;

[0128] Downstream primer sequence: 5'-ggggtacttcagggtgagga-3', as shown in SEQ ID NO:4.

[0129] All operations were performed on ice.

[0130] The amplification program was: 95°C, 10 min, (95°C, 15 s, 60°C, 60 s)*45 cycles. SYBR Green was used as a fluorescent marker, and the PCR reaction was performed on a Light Cycler fluorescent real-time quantitative PCR instrument. The target band was determined by melting curve analysis and electrophoresis. ΔΔ The relative quantification was performed by CT method.

[0131] 2. Results

[0132] The target bands were determined by melting curve analysis and electrophoresis. ΔΔ The relative quantitative results of CT method are as follows Figure 1 The results showed that compared with the healthy control group, the expression level of FAM210B mRNA in the peripheral blood cells of multiple myeloma patients was significantly upregulated ( Figure 1 ). In this way, the qPCR diagnostic kit based on FAM210B gene detection can be applied to the diagnosis of multiple myeloma.

[0133] The present invention uses high-throughput gene expression profiling sequencing to find that compared with healthy controls, the expression level of FAM210B mRNA in peripheral blood cells of multiple myeloma patients is significantly upregulated (Table 1). This result shows the feasibility of developing a qPCR kit based on FAM210B mRNA detection for diagnosing multiple myeloma. By developing a qPCR kit based on FAM210B mRNA detection and the kit can effectively detect the occurrence of multiple myeloma ( Figure 1). These results show that the qPCR diagnostic kit based on FAM210B gene detection can be used in the diagnosis of multiple myeloma. In addition, the present invention provides a new method and new target for the diagnosis and treatment of multiple myeloma cells.

[0134] The above is only a preferred embodiment of the present invention, which is only to help those skilled in the art to better understand the technical solution of the present invention, and does not limit the present invention in any form. The present invention is not limited to the above embodiments. Any person skilled in the art can make some changes or modify them into equivalent embodiments with the same changes without departing from the scope of the technical solution of the present invention. However, any simple modification, equivalent change and modification made to the above embodiments according to the technical essence of the present invention without departing from the technical solution of the present invention still falls within the scope of the technical solution of the present invention.

Claims

1. Application of a quantitative polymerase chain reaction (qPCR) amplification kit based on FAM210B gene in the diagnosis of multiple myeloma, It is characterized in that The diagnostic kit comprises qPCR primers that can be used to amplify the FAM210B gene, and the primers are: The upstream primer sequence is 5'-TCTCTGATGCAGGGCACTTG-3', as shown in SEQ ID NO: 1; the downstream primer sequence is 5'-CTCAGCACGCTCCTGTTACT-3', as shown in SEQ ID NO:

2.

2. A multiple myeloma diagnostic kit based on the FAM210B gene, It is characterized in that The diagnostic kit comprises qPCR primers for the FAM210B gene, and the primers are: The upstream primer sequence is 5'-TCTCTGATGCAGGGCACTTG-3', as shown in SEQ ID NO: 1; the downstream primer sequence is 5'-CTCAGCACGCTCCTGTTACT-3', as shown in SEQ ID NO:

2.

3. The diagnostic kit according to claim 2, It is characterized in that The diagnostic kit also contains a pair of primers for the housekeeping gene β-actin, and the primers are: Upstream primer sequence: 5'-ctcgcctttgccgatcc-3', as shown in SEQ ID NO: 3; Downstream primer sequence: 5'-ggggtacttcagggtgagga-3', as shown in SEQ ID NO:

4.

4. The diagnostic kit according to claims 1-3, It is characterized in that The diagnostic kit also includes a qPCR reaction system: SYBR Green fluorescent dye, PCR buffer, and dNTPs.

5. The diagnostic kit according to claims 1-4, It is characterized in that The PCR buffer contains: 200mM (NH4) 2 SO 4 , 20mM KCl, 2.5mM MgCl 2 .

6. The diagnostic kit according to any one of claims 1 to 5, It is characterized in that The diagnostic kit also includes an M-MLV reverse transcription system; the reverse transcription system includes T repeat oligonucleotide OligodT, M-MLV reverse transcriptase, RNase inhibitor, dNTPs and reverse transcription reaction solution (15mM MgCL2, 370mM KCL, 50mM DTT, 250mM Tris-HCL with pH 8.3).

7. The diagnostic kit according to any one of claims 1 to 6, It is characterized in that The diagnostic kit further comprises an RNA extraction reagent, which comprises Trizol, chloroform, isopropanol and 75% ethanol.